Spots Global Cancer Trial Database for A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
Official Title: A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors
Study ID: NCT00670189
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Rochester, Rochester, Minnesota, United States
Southwest Texas Addiction Research And Tech (Start) Center, San Antonio, Texas, United States
Local Institution, Toronto, Ontario, Canada
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
